Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

2014 ACR/ARHP Annual Meeting: Lupus Nephritis

Mary Beth Nierengarten  |  Issue: February 2015  |  February 1, 2015

BOSTON—For patients with lupus nephritis, multi-targeted therapies combining drugs similar to what oncologists do now to treat cancer is the future of treatment for this complication of lupus, according to Michelle Petri, MD, MPH, professor of medicine, director, Lupus Center, Johns Hopkins University School of Medicine, Baltimore, who emphasized the need for aggressive therapy to achieve a goal of complete response and remission.

Adding rituximab to the mix may permit reducing and avoiding altogether the use of long-term steroids if an international, multicenter trial just underway can demonstrate the efficacy and safety of a rituximab regimen sans steroids for lupus nephritis, according to Liz Lightstone, MD, professor of renal medicine, Imperial Lupus Centre, Imperial College London, Hammersmith Hospital, London, U.K.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

These were among the issues discussed in a session titled, Forefronts in Lupus Nephritis, at the ACR/ARHP Annual Meeting in Boston in November 2014, in which Drs. Petri and Lightstone focused on the future of combination therapies that can both effectively treat lupus nephritis, as well as reduce side effects and improve quality of life in these patients.

Multi-Targeted Treatment Approach

For Dr. Petri, treatment of lupus nephritis requires an aggressive approach that includes a variety of treatments targeted at multiple issues. For acute treatment, she described a combination of multi-targeted therapies that she uses, including ACE/ARB to control blood pressure, protect renal function and, perhaps, reduce fibrosis; hydroxychloroquine, which when used with mycophenolate mofetil (MMF) improves complete renal response rates; and vitamin D, which shows a modest benefit on disease activity and urine protein/creatinine levels. Achieving a 25-hydroxy level of 40 or above significantly helps reduce protein/creatinine levels.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

For pregnant women, she emphasized the need for continual treatment of lupus nephritis because data show that renal activity can worsen during and after pregnancy and recommended azathioprine and cyclosporine or tacrolimus, but never MMF.

She also emphasized limiting exposure to steroids, saying that she typically doesn’t give high doses of prednisone to patients with mild Class III or IV disease nor any prednisone to some patients with Class II disease. Although guidelines recommend prednisone in all patients with Class IV disease, she highlighted that data also show that prednisone increases the risk of cardiovascular events, and therefore, she emphasized that a high dose is not needed in all patients. She also suggested that oral steroids may not be necessary at all in patients with mild nephritis.

For maintenance therapy, she uses MMF on the basis of results of the ALMS maintenance trial that showed the superiority of MMF over azathioprine.1 She offered a number of hints for administering the drug so that patients can better tolerate it (see Table 1).

Table 1: Hints for Using MMF as Maintenance Therapy for Lupus Nephritis
Begin at an effective dose of 1,000 mg twice daily for one month. If the urine protein is not improving after one month, she ups the dose to 1,500 mg twice a day.
Split dose to take half in the morning and half at night. Because patients often forget their evening dose, she recommends they use their smartphone or some other technique to remind them.
Recognize the different dosing requirements based on ethnicity. Caucasians and Asians usually require 2,000 mg per day and African Americans often require 3,000 mg per day.
Get trough levels for monitoring whether patients are medication adherent.

 

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:2014 ACR/ARHP Annual MeetingAC&RAssociation of Rheumatology Professionals (ARP)drugLupus nephritis

Related Articles

    Immunosuppressive Treatment for Lupus in the Next Decade

    April 13, 2011

    It’s time for a new strategy

    Tacrolimus Use for Lupus Nephritis Raises Debate over Role in North American Population

    October 10, 2016

    The following summary regarding use of tacrolimus (TAC) in lupus nephritis highlights a number of debatable points. Although the role of TAC in lupus nephritis remains unproved for North American populations, it might be an excellent option in some clinical situations. These situations include lupus flare during pregnancy and also for lupus nephritis when the…

    Reading Rheum

    October 1, 2009

    Handpicked Reviews of Contemporary Literature

    Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances

    December 1, 2014

    Rheumatology experts review history of LN, offer explanations for roadblocks to better therapies

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences